Curiox Biosystems, a Singapore-based developer of bioinstrumentation solutions used in cell analysis and therapy for the pharmaceutical and biotech industries, secured a Series B funding of US$15M.
Backers included KB Investment, IMM Investment, QUAD Investment, HB Investment, DAYLI Investment, and SV Investment.
The company intends to use the funds to scale up and accelerate the commercialzsation activities globally.
Led by Dr. Namyong Kim, founder and CEO, Curiox Biosystems is a bioinstrumentation company spun out of the Agency for Science, Technology, and Research (A*STAR) in Singapore. Curiox plans to pursue an IPO on the Korean stock exchange, KOSDAQ in the next 36 months to entrench its position as a dynamic bioinstrumentation company in the region.
The new board is led by Mr Sim Giok Lak, Chairman of ZIG, and includes Dr Kim Namyong, founder CEO of CURIOX, Mr Sim Kok Hwee, CEO of ZIG, Dr Hong Youngtae, Managing Director of QUAD Investment, and Ms Aleum Lee, VP of IMM Investment.
A Global Scientific Advisory Panel shall be established and led by Professor Alex Matter, who recently retired as the Executive Director of the Experimental Therapeutics Center (ETC), A*Star. Prof. Matter also chairs the Scientific Advisory Committee of Institute Pasteur Korea. Prior to leading ETC, Prof. Matter was the Global Head of Oncology Research at Novartis.